Angiotensin II does not increase renal prostaglandin E2 in response to pressure reduction.
Whether angiotensin II (Ang II) stimulates renal secretion of prostaglandin E2 (PGE2) synthesized in response to pressure reduction was examined. PGE2 and Ang II in aortic and renal venous plasma were measured before and during renal arterial constriction in anesthetized dogs, with or without an intrarenal arterial infusion of an Ang II antagonist, losartan potassium (1 mg/min), or saralasin (3 micrograms/min). In other anesthetized dogs, two doses of Ang II (30 and then 300 ng/min) were infused into the renal artery, and plasma Ang II levels and renal PGE2 secretion were measured. When renal perfusion pressure was reduced to 75 and 45 mm Hg by constriction, the renal secretion of PGE2 increased seven- and fourfold, respectively. Ang II levels in the renal venous plasma increased from 6.6 +/- 1.8 to 21.7 +/- 7.4 and then 48.1 +/- 15.3 pg/ml (both P less than 0.05) as the pressure decreased. Neither losartan nor saralasin suppressed the response of renal PGE2 secretion to the pressure reduction. The intrarenal infusion of Ang II (30 ng/min) elevated the Ang II level in the renal venous plasma from 9.8 +/- 4.6 to 33.7 +/- 4.2 pg/ml (P less than 0.01), but did not increase PGE2 secretion. The higher dose (300 ng/min) of Ang II increased it, but the Ang II level in the renal venous plasma was 166 +/- 63 pg/ml. These results suggest that the greater part of the increased renal synthesis of PGE2 in response to pressure reduction is not mediated by Ang II.
Imanishi
M
M
Division of Hypertension and Renal Diseases, National Cardiovascular Center, Osaka, Japan.
Akabane
S
S
Kawamura
M
M
Matsushima
Y
Y
Kuramochi
M
M
Omae
T
T
D000804:Angiotensin II / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D000818:Animals; D001713:Biphenyl Compounds / Q000494:pharmacology; D001794:Blood Pressure / Q000502:physiology; D015232:Dinoprostone / Q000096:biosynthesis* / Q000378:metabolism; D004285:Dogs; D005260:Female; D007093:Imidazoles / Q000494:pharmacology; D007261:Infusions, Intra-Arterial; D007668:Kidney / Q000187:drug effects* / Q000378:metabolism; D019808:Losartan; D008297:Male; D012079:Renal Circulation / Q000187:drug effects / Q000502:physiology; D012083:Renin / Q000378:metabolism; D012504:Saralasin / Q000494:pharmacology; D013777:Tetrazoles / Q000494:pharmacology
D001713:Biphenyl Compounds; D007093:Imidazoles; D013777:Tetrazoles; D000804:Angiotensin II; D012083:Renin; D012504:Saralasin; D019808:Losartan; D015232:Dinoprostone